GlassScriptPhysician profile
Olivia Ann Couch
NPI 1598209330
$6,330.86
in general payments reported to CMS, 2019-2025
25 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $1,767 · 2023: $1,706 · 2024: $928 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,667.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,194.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,038.28 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $542.81 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $538.85 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $449.58 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $397.57 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $376.96 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $301.91 | 2021-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $247.26 | 2021-2025 | Spravato |
| Lundbeck LLC | $228.09 | 2022-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $150.37 | 2023 | Auvelity |
| Corium, LLC | $145.29 | 2022-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $135.92 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $123.88 | 2021-2022 | |
| Almatica Pharma LLC | $94.17 | 2022-2025 | Loreev Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $72.85 | 2021-2024 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $72.76 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $54.12 | 2022 | |
| Tris Pharma INC | $41.90 | 2025 | Dyanavel Xr |
| Eisai INC. | $31.17 | 2021 | |
| Harmony Biosciences LLC | $25.32 | 2023 | Wakix |
| Jazz Pharmaceuticals INC. | $18.69 | 2021 | |
| Merck Sharp & Dohme LLC | $17.50 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.63 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $14.96 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Couch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.